A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

NCT ID: NCT05197036

Last Updated: 2024-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

299 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-21

Study Completion Date

2028-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical trial investigating the safety and effectiveness of Smith and Nephew's FDA-approved Porous Total Knee System, which is used to replace worn away and diseased knee joints. The aim of this study is to show that most patients who receive the Porous Total Knee System have reduced pain, greater mobility and a long-lasting implant post-surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who need a total knee replacement or have recently had a total knee replacement with the Smith and Nephew Porous Total Knee System will be enrolled into the study. Before surgery X-rays will be collected and questionnaires will be administered which ask the patient about knee pain, activities of daily living, quality of life and how they feel about their knee. The same X-rays and questionnaires will be asked before surgery and then after surgery at various intervals up to 5 years post-surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis Post-traumatic Arthritis Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEGION Porous CR with Hydroxyapatite

Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR with HA femoral component (min 117 subjects)

Total Knee Arthroplasty

Intervention Type PROCEDURE

A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.

LEGION Porous CR without Hydroxyapatite

Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR without HA femoral component (min 117 subjects)

Total Knee Arthroplasty

Intervention Type PROCEDURE

A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Total Knee Arthroplasty

A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Total Knee Replacement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A) Subject needing primary TKA due to degenerative joint disease (primary diagnosis of osteoarthritis), post-traumatic arthritis or inflammatory arthritis.

OR

B) Subject has undergone primary TKA with Smith+Nephew Porous knee system in past 12 months to repair degenerative joint disease, post- traumatic arthritis or inflammatory arthritis and all the following conditions have been met:
* Preoperative KOOS JR and radiographs have been obtained
* 6-Month KOOS JR and radiographs have been obtained or these can be collected prospectively in window per schedule of events
2. Subject agrees to consent and to follow the prospective study visit schedule (as defined in the study protocol and informed consent form) by signing the Independent Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form.
3. Subject is willing to attend study follow-up visits for up to five (5) years post-surgery.
4. Subject is able to read, understand, and communicate responses to Patient Reported Outcome assessments.
5. Subject is 18-80 years old (inclusive).

Exclusion Criteria

1. Subject received TKA on the contralateral knee as a revision for a previously failed total or unicondylar knee arthroplasty.
2. Subject has a Body Mass Index (BMI) ≥ 40 at time of surgery.
3. Subject has ipsilateral hip arthritis resulting in flexion contracture.
4. At the time of enrolment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary total knee or unicondylar knee arthroplasty.
5. Subject has a condition that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
6. Subject has a known allergy to one or more of its components of the study device.
7. Any subject with hardware present in distal femur or proximal tibia.
8. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
9. Subject is entered in another drug, biologic, or device study or has been treated with an investigational product in the past 30 days.
10. Subject, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, drug or alcohol abuse.
11. Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits.
12. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
13. Subjects who have participated previously in this clinical trial and who have been withdrawn.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amir Kamali

Role: STUDY_DIRECTOR

Smith & Nephew, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emory Orthopaedics and Spine Hospital

Atlanta, Georgia, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

The Core Institute

Novi, Michigan, United States

Site Status

Syracuse Orthopedic Specialists

East Syracuse, New York, United States

Site Status

NYU Langone Health Orthopedic Hospital

New York, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

Duke Health

Morrisville, North Carolina, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Erlanger Health

Chattanooga, Tennessee, United States

Site Status

UTHealth

Houston, Texas, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

St George and Sutherland Centre for Clinical Orthopaedic Research

Sydney, New South Wales, Australia

Site Status

OrthoSport Victoria

Melbourne, Victoria, Australia

Site Status

Robina Hospital

Robina, Victoria, Australia

Site Status

The Avenue Hospital

Windsor, Victoria, Australia

Site Status

Concordia Joint Replacement Group

Winnipeg, Manitoba, Canada

Site Status

Sint Maartenskliniek

Ubbergen, Ubbergen,, Netherlands

Site Status

Medical Center Leeuwarden

Leeuwarden, , Netherlands

Site Status

Umeå University Hospital

Umeå, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Netherlands Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

POROUS.TKA.SYSTEM.2021.07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

10003 PRO Current Products
NCT01497730 COMPLETED
The 3DKnee™ System: A Post-Market Study
NCT00764673 COMPLETED PHASE4
LEGION™ Primary Safety and Efficacy
NCT04040985 TERMINATED NA